JP2000513805A5 - - Google Patents

Download PDF

Info

Publication number
JP2000513805A5
JP2000513805A5 JP1997529635A JP52963597A JP2000513805A5 JP 2000513805 A5 JP2000513805 A5 JP 2000513805A5 JP 1997529635 A JP1997529635 A JP 1997529635A JP 52963597 A JP52963597 A JP 52963597A JP 2000513805 A5 JP2000513805 A5 JP 2000513805A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP1997529635A
Other languages
English (en)
Japanese (ja)
Other versions
JP4205165B2 (ja
JP2000513805A (ja
Filing date
Publication date
Priority claimed from GBGB9609521.1A external-priority patent/GB9609521D0/en
Priority claimed from GBGB9621314.5A external-priority patent/GB9621314D0/en
Application filed filed Critical
Priority claimed from PCT/GB1997/001250 external-priority patent/WO1997042222A1/en
Publication of JP2000513805A publication Critical patent/JP2000513805A/ja
Publication of JP2000513805A5 publication Critical patent/JP2000513805A5/ja
Application granted granted Critical
Publication of JP4205165B2 publication Critical patent/JP4205165B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP52963597A 1996-05-08 1997-05-08 Cdk4活性の阻害のための方法と手段 Expired - Fee Related JP4205165B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9609521.1A GB9609521D0 (en) 1996-05-08 1996-05-08 Substances and their therapeutic use
GB9609521.1 1996-10-09
GB9621314.5 1996-10-09
GBGB9621314.5A GB9621314D0 (en) 1996-10-09 1996-10-09 Substances and their therapeutic use
PCT/GB1997/001250 WO1997042222A1 (en) 1996-05-08 1997-05-08 Methods and means for inhibition of cdk4 activity

Publications (3)

Publication Number Publication Date
JP2000513805A JP2000513805A (ja) 2000-10-17
JP2000513805A5 true JP2000513805A5 (Direct) 2005-01-13
JP4205165B2 JP4205165B2 (ja) 2009-01-07

Family

ID=26309279

Family Applications (1)

Application Number Title Priority Date Filing Date
JP52963597A Expired - Fee Related JP4205165B2 (ja) 1996-05-08 1997-05-08 Cdk4活性の阻害のための方法と手段

Country Status (7)

Country Link
US (3) US6962792B1 (Direct)
EP (1) EP0898580B9 (Direct)
JP (1) JP4205165B2 (Direct)
AT (1) ATE333465T1 (Direct)
AU (1) AU2707797A (Direct)
DE (2) DE69736351T4 (Direct)
WO (1) WO1997042222A1 (Direct)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997042222A1 (en) 1996-05-08 1997-11-13 Cyclacel Limited Methods and means for inhibition of cdk4 activity
GB9727277D0 (en) * 1997-12-23 1998-02-25 Medical Res Council Assay
DE69907151D1 (de) * 1998-02-18 2003-05-28 Theryte Ltd Krebsbehandlung
BR9907965A (pt) * 1998-03-23 2000-12-12 Du Pont Fragmento de ácido nucléico isolado, gene quimérico, célula hospedeira transformada, polipetìdios, processo de alteração do nìvel de expressão de uma proteìna ciclina em uma célula hospedeira, método de obtenção de um fragmento de ácido nucleìco, produto e método de avaliação de pelo menos um composto quanto à sua capacidade de inibir a atividade de uma proteìna ciclina
EP1338652A3 (en) * 1998-03-23 2004-05-19 E.I.Du pont de nemours and company Plant cell cyclin genes
WO2000038733A1 (en) * 1998-12-24 2000-07-06 Ucb S.A. Peptidic product, process and composition
CA2367385A1 (en) * 1999-04-07 2000-10-12 E.I. Du Pont De Nemours And Company Cell cycle in plants
GB9928323D0 (en) * 1999-11-30 2000-01-26 Cyclacel Ltd Peptides
GB2369823B (en) * 1999-11-30 2003-06-04 Cyclacel Ltd Assays for cyclin-interacting compounds
US7449544B2 (en) 1999-11-30 2008-11-11 Cyclacel Limited p21 peptides
US20050153894A1 (en) * 1999-11-30 2005-07-14 Cyclacel Limited p21 peptides
GB0012528D0 (en) * 2000-05-23 2000-07-12 Univ Palackeho Triterpenoid derivatives
GB0030378D0 (en) 2000-12-13 2001-01-24 Cyclacel Ltd Compound
WO2004015073A2 (en) * 2002-08-07 2004-02-19 Exelixis, Inc. MP21S AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE
GB0229151D0 (en) 2002-12-13 2003-01-15 St Georges Entpr Ltd Product and method
WO2005040207A1 (en) * 2003-10-20 2005-05-06 F. Hoffmann-La Roche Ag Tyrosine phosphorylation of cdk inhibitor proteins of the cip/kip family
AU2004285745A1 (en) * 2003-10-21 2005-05-12 Cyclacel Limited Pyrimidin-4-YL-3, 4-thione compounds and their use in therapy
GB0402653D0 (en) * 2004-02-06 2004-03-10 Cyclacel Ltd Compounds
GB0411791D0 (en) * 2004-05-26 2004-06-30 Cyclacel Ltd Compounds
ES2403558T3 (es) 2004-08-27 2013-05-20 Cyclacel Limited Inhibidores purínicos y pirimidínicos de CDK y su uso para el tratamiento de enfermedades autoinmunitarias
JP2009500314A (ja) * 2005-06-29 2009-01-08 セント ジョージス エンタープライシス リミテッド 遺伝子調節
WO2009070650A1 (en) * 2007-11-26 2009-06-04 The Research Foundation Of State University Of New York Small molecule cancer treatments that cause necrosis in cancer cells but do not affect normal cells
US9040046B2 (en) 2011-01-31 2015-05-26 Kai Xu Sodium pump antibody agonists and methods of treating heart disease using the same
AU2019247554A1 (en) 2018-04-06 2020-11-26 Oncolyze, Inc. Compositions for use in lysis of selective cancer cells
SI3849537T1 (sl) 2018-09-10 2025-03-31 Mirati Therapeutics, Inc. Kombinirane terapije
CN118324906A (zh) * 2024-06-14 2024-07-12 上海交通大学医学院附属上海儿童医学中心 p21特异性修饰的抗体及制备方法和应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2759164A1 (de) 1977-12-31 1979-07-12 Basf Ag Photopolymerisierbare ueberzugs- und aufzeichnungsmaterialien, enthaltend einen photoinitiator und eine organische halogenverbindung
US5229018A (en) 1986-02-24 1993-07-20 Forrest Gabriel T Completion and workover fluid for oil and gas wells comprising ground peanut hulls
FR2662698A1 (fr) * 1990-06-05 1991-12-06 Centre Nat Rech Scient Nouveaux facteurs de croissance neurotropes comprenant un peptide homeoboite.
US5596079A (en) 1991-12-16 1997-01-21 Smith; James R. Mimetics of senescent cell derived inhibitors of DNA synthesis
US5302706A (en) 1991-12-16 1994-04-12 Baylor College Of Medicine Senescent cell derived inhibitors of DNA synthesis
ATE242806T1 (de) 1992-10-16 2003-06-15 Cold Spring Harbor Lab Umlagerung des cyclin komlexes und seine darauf bezogenen anwendungen
GB9305448D0 (en) 1993-03-17 1993-05-05 British Tech Group Semiconductor structure and method of manufacturing same
AU692794B2 (en) 1993-08-30 1998-06-18 Baylor College Of Medicine Senescent cell-derived inhibitors of DNA synthesis
WO1995013375A1 (en) 1993-11-10 1995-05-18 The Johns Hopkins University Tumor suppressor waf1
WO1995031995A1 (en) 1994-05-24 1995-11-30 Baylor College Of Medicine Mimetics of senescent cell derived inhibitors of dna synthesis
GB9422175D0 (en) 1994-11-03 1994-12-21 Univ Dundee Indentification of the p21 waf1-pcna interaction site and therapeutic applications thereof
GB9509557D0 (en) 1995-05-11 1995-07-05 Univ Dundee PCNA binding substance
AU6548396A (en) 1995-07-20 1997-02-18 Worcester Foundation For Biomedical Research, Inc. Methods for selectively killing or inhibiting the growth of cells expressing the waf1 gene
US5672508A (en) 1996-01-23 1997-09-30 Mitotix, Inc. Inhibitors of cell-cycle progression, and uses related thereto
WO1997042222A1 (en) 1996-05-08 1997-11-13 Cyclacel Limited Methods and means for inhibition of cdk4 activity

Similar Documents

Publication Publication Date Title
JP2000502280A5 (Direct)
JP2000508686A5 (Direct)
JP2001502189A5 (Direct)
JP2000501771A5 (Direct)
JP2000501599A5 (Direct)
JP2000501018A5 (Direct)
JP2000508076A5 (Direct)
JP2001505892A5 (Direct)
JP2000500055A5 (Direct)
JP2000512140A5 (Direct)
JP2000500026A5 (Direct)
JP2000502472A5 (Direct)
JP2000501825A5 (Direct)
JP2000502425A5 (Direct)
JP2000502485A5 (Direct)
JP2000502568A5 (Direct)
JP2000501774A5 (Direct)
JP2000502570A5 (Direct)
JP2000505485A5 (Direct)
JP2001506933A5 (Direct)
JP2000501876A5 (Direct)
JP2001506378A5 (Direct)
JP2000501744A5 (Direct)
JP2000502316A5 (Direct)
JP2000502714A5 (Direct)